- Circulating anti-Müllerian hormone (AMH) is linked to elevated breast cancer risk, with a 60% increase for women in the top vs bottom quartile of AMH.
Why this matters
- AMH has the potential to be one of the few breast cancer biomarkers.
- A nested case-control design (n=3122 breast cancers) was conducted across 10 prospective cohorts.
- AMH was assessed by high-sensitivity enzyme-linked immunoabsorbent assay.
- Funding: NIH to Sister Study; Avon Foundation for Women.
- There was a 60% increase in odds of breast cancer for women in the top quartile of AMH vs the bottom AMH quartile (OR, 1.60; 95% CI, 1.31-1.94).
- The trend was significant only for tumors that were positive for both estrogen receptor and progesterone receptor in the top vs bottom AMH quartile (OR, 1.96; 95% CI, 1.46-2.64).
- The association between AMH and breast cancer applied to both premenopausal (OR, 1.35; 95% CI, 1.05-1.73) and postmenopausal (OR, 1.61; 95% CI, 1.03-2.53) breast cancer.
- Relatively small sample size.